Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
OABI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.10 - $6.55
Previous CloseN/A
Volume80.31K
Average Volume (3M)532.11K
Market Cap
$469.53M
Enterprise Value$397.58M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 27, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding121,012,580
10 Day Avg. Volume534,790
30 Day Avg. Volume532,111
Standard Deviation0.15
R-Squared0.00085
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.01
Price to Cash Flow (P/CF)-17.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.64
Enterprise Value/Ebitda-6.35
Forecast
1Y Price Target
$7.00Price Target Upside91.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
OmniAb News
PremiumCompany Announcements
OmniAb Reports Third Quarter 2024 Financial Results
PremiumCompany Announcements
OmniAb Board Reshuffles Following Tamaroff’s Departure
PremiumStock Analysis & Ideas
Insiders Load Up on These 2 Stocks — Here’s Why You Should Follow---
Bulls Say, Bears Say
Bulls Say
Financial MilestonesOABI's current partner pipeline from preclinical to registration comes with $550M+ in potential milestones, supporting management's belief it has adequate capital to reach cash flow profitability.
Operational EfficiencyManagement reaffirmed that cash burn is expected to be even lower in 2025 compared to 2024, indicating improved operational efficiency.
Partnership ExpansionOmniAb entered into three new platform license agreements with 92Bio, Memorial Sloan Kettering Cancer Center, and Queen Mary University of London, highlighting its commitment to building a diversified portfolio backed by differentiated technologies.
Bears Say
Market ChallengesManagement noted continued macro challenges from large pharma pipeline prioritization and bifurcated funding of small biotechs.
Revenue MissQ3 revenues of $4M missed consensus largely due to a delayed milestone payment and a drop in ion channel service revenues.
Revenue ShortfallThe company reported revenue of $4.2 million compared to the estimate of $10.9 million, reflecting a significant shortfall.
---
Ownership Overview
32.16% Insiders
19.83% Mutual Funds
12.86% Other Institutional Investors
26.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $3.10 and its highest was $6.55 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $469.53M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is Mar 27, 2025 which is in 32 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on Nov 12, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.022.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.1.
How many shares outstanding does OmniAb have?
OmniAb has 121,012,580 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -9.354%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
---
OmniAb Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (91.78% Upside)
$7.00 (91.78% Upside)
Hedge Fund Trend
Increased
By 371.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.75%
12-Months-Change
Fundamentals
Return on Equity
-20.45%
Trailing 12-Months
Asset Growth
-15.36%
Trailing 12-Months
Company Description
OmniAb
Avista Public Acquisition Corp II is a blank check company.
---
OABI Company Deck
---
OABI Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in active programs and new partnerships, along with positive advancements in clinical developments. However, financial challenges persist with a decrease in revenue and sustained net loss, compounded by industry-wide pressures.Read More>---
OABI Stock 12 Month Forecast
Average Price Target
$7.00
▲(91.78% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Xenon
―
Argenx Se
―
Adaptive Biotechnologies
―
Best Analysts Covering OABI
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+8.79%
reiterated a buy rating 3 months ago
Copying Puneet Souda's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +8.79% per trade.
---